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Abstract
Human African Trypanosomiasis (HAT) is caused by two trypanosome sub-species, Trypanosoma brucei rhodesiense and
Trypanosoma brucei gambiense. Drugs available for the treatment of HAT have significant issues related to difficult
administration regimes and limited efficacy across species and disease stages. Hence, there is considerable need to find new
alternative and less toxic drugs. An approach to identify starting points for new drug candidates is high throughput
screening (HTS) of large compound library collections. We describe the application of an Alamar Blue based, 384-well HTS
assay to screen a library of 87,296 compounds against the related trypanosome subspecies, Trypanosoma brucei brucei
bloodstream form lister 427. Primary hits identified against T.b. brucei were retested and the IC50 value compounds were
estimated for T.b. brucei and a mammalian cell line HEK293, to determine a selectivity index for each compound. The
screening campaign identified 205 compounds with greater than 10 times selectivity against T.b. brucei. Cluster analysis of
these compounds, taking into account chemical and structural properties required for drug-like compounds, afforded a
panel of eight compounds for further biological analysis. These compounds had IC50 values ranging from 0.22 mM to 4 mM
with associated selectivity indices ranging from 19 to greater than 345. Further testing against T.b. rhodesiense led to the
selection of 6 compounds from 5 new chemical classes with activity against the causative species of HAT, which can be
considered potential candidates for HAT early drug discovery. Structure activity relationship (SAR) mining revealed
components of those hit compound structures that may be important for biological activity. Four of these compounds have
undergone further testing to 1) determine whether they are cidal or static in vitro at the minimum inhibitory concentration
(MIC), and 2) estimate the time to kill.
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Introduction
Human African Trypanosomiasis (HAT) is caused by infection
with either the trypanosome subspecies Trypanosoma brucei gambiense
or Trypanosoma brucei rhodesiense. Decreasing numbers of reported
new cases over the last 10 years have been reported - from over
25,000 in 2000 to 10,000 in 2009 - of which over 95% are caused
by T.b. gambiense [1]. However, the World Health Organization
(WHO) currently estimates the actual number of cases to be
around 30,000 [http://www.who.int/mediacentre/factsheets/
fs259/en/]. HAT is mainly confined within sub-Saharan Africa,
where the vector, the parasite and the animal reservoirs co-exist
[2]. HAT occurs in two stages, whereby the first stage, also called
the haemolymphatic stage, corresponds to the invasion of lymph,
blood and other tissues by the trypanosomes, and the second stage
is associated with parasites crossing the blood-brain barrier and
invading the central nervous system (CNS). Symptoms of the
second stage of the disease include mental impairment, severe
headaches, fever, chronic encephalopathy and an eventual,
terminal somnolent state, if the disease remains untreated.
There are currently few drugs available for the treatment of
HAT. For the first stage of the disease, suramin is used as the
treatment for T.b. rhodesiense and pentamidine for T.b. gambiense
infections. Neither of these drugs are able to cross the blood brain
barrier and therefore are not effective against the CNS resident,
second stage of the disease. In addition, both of these treatments
have significant side effects, often resulting in reduced compliance.
Suramin is associated with exfoliative dermatitis [2] and renal
failure [3], whilst pentamidine use has been correlated with
diabetes mellitus and nephrotoxicity [4]. Melarsoprol, an orga-
noarsenic compound, is most frequently used for the treatment of
the second stage of the disease as it is effective against both
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trypanosome subspecies. However, there have been reports of high
failure rates with melarsoprol, and although resistance has not
definitively been proven, this does highlight the need for
alternative therapies [5]. As a consequence of treatment with
melarsoprol, encephalopathic syndromes occur in 5 to 10% of all
of treated patients causing between 10 to 70% fatality, depending
on the literature source [6–10]. The alternative therapy for the
second stage of the disease, eflornithine, is a less toxic and a safer
alternative however it is unfortunately not effective against T.b.
rhodesiense. There are also problems with affordability of eflor-
nithine in many of the disease-endemic countries [11]. The recent
inclusion of nifurtimox to the WHO Essential Medicine List in
2009 [11,12], to be used only in combination with eflornithine for
the treatment for the second stage of HAT caused by T.b.
gambiense, is a significant milestone. Nifurtimox-eflornithine com-
bination therapy (NECT) has a shorter and simplified adminis-
tration regimen and is the only significantly improved treatment
option made available to patients in the past 25 years. NECT is
now used as the first line treatment for stage 2 HAT caused by T.b.
gambiense [13,14]. There was some hope for an oral drug for
treating the first stage of HAT with the compound, pafuramidine
(DB289). Unfortunately, in an extended phase III trial, liver
toxicity and delayed renal insufficiency were observed in a number
of patients and consequently the program was discontinued in
2008 [15]. Recent advances which hold promise include the
identification of orally bioavailable oxaborole 6-carboxamides
which have been shown to cure a murine model of late stage CNS
HAT [16] and an orally active benzoxaborole has been selected to
enter pre-clinical studies [17]. Despite this there is still a need for
the discovery of additional trypanocidal compounds with the
potential for further progression in the drug discovery pipeline for
HAT. This is particularly evident when one takes into account the
toxicity of traditional treatments, the inability of the newer less
toxic combination therapies to treat both subspecies or both
disease stages, and the historical 90% failure rate of drugs entering
the clinic to reach the market [18].
One method for the identification of active compounds against
HAT is the application of high throughput screening (HTS)
methods. HTS against T.b. brucei targets, such as the enzyme
TbHK1 (Trypanosoma brucei hexokinase 1) [19] have recently been
reported. A potential drawback to target-based HTS is that
screening hits may have to undergo significant medicinal
chemistry optimisation to impart favourable properties for low
serum binding, high membrane permeability and high aqueous
solubility in order to register potent activity against the parasite.
Whole cell screening is becoming increasingly popular, as although
elucidation of the biological target requires deconvolution, active
compounds are discovered under conditions that are already
physiologically relevant. We have recently reported the develop-
ment of a 384 Alamar Blue based 384-well viability assay for HTS
screening of compounds against T.b. brucei [20]. For this assay, and
indeed many in vitro models for studies of HAT, the human non-
infective sub-species T.b. brucei blood stream form has been utilised
[21]. Alamar Blue (containing resazurin) is a fluorometric/
colorimetric REDOX indicator. In a reducing environment
caused by metabolising cells, resazurin is converted to resorufin,
a fluorescent end product. This reagent has been used routinely as
an indicator of the viability of mammalian cells. It is thought that
cells may induce a reduction in the medium or reduce Alamar
Blue intracellularly [22]. We have shown that the fluorescent
Alamar Blue signal is linear to the number of T.b. brucei cells in a
well, therefore it provides a good indication of viable cell numbers
[20]. For this reason we have used this assay to assess the activity
of compounds against T.b. brucei whole cells.
Here we describe the HTS of a compound library (WEHI 2003
collection [23]) using a 384-well whole cell T.b. brucei assay, and
the retesting of the identified active compounds against both T.b.
brucei and a human cell line, HEK293, in order to assess
mammalian cytotoxicity. The reproducibility of both the primary
and retest assays were evaluated by the Z’-factor (Z’), a coefficient
which reflects the reproducibility of the assay and is calculated
using the positive and negative controls. The Z’ takes into account
the control signal range and variation, with a value close to 1
considered highly reproducible [24]. Reference compound activ-
ities for the T.b. brucei assay were compared with previously
published results for the same assay format [20,25]. Selectively
active compounds were subjected to rigorous chemical analysis
taking into account drug like and non-drug like structural
properties. The selectivity index (SI) was defined as the HEK293
IC50 values divided by the T.b. brucei IC50 value. The compounds
selected, with the initial criteria of an SI of greater than 10 times,
were ultimately shown to have SI values ranging from 19 and a
predicted value greater than 345. Further testing against T.b.
rhodesiense revealed five new classes of active compounds that are
recommended as chemical leads for the potential development of
therapeutics against HAT. SAR mining revealed components of
these hit compound structures that may be important for the
observed biological activity, and these will be outlined. Based on
compound availability, four compounds were selected for further
biological profiling by estimating the time to kill and assessment if
the compound action is cidal.
Methods
In vitro culture of T.b. brucei and HEK293 cells
T.b. brucei lister 427 cells [26] were maintained in log phase
growth in 25 cm2 tissue culture flasks (Corning, NY, USA) by sub-
culturing at either 24 or 48 hour intervals. Cells were grown in
Author Summary
Human African Sleeping Sickness (HAT) is a disease caused
by sub-species of Trypanosoma. The disease affects
developing countries within Africa, mainly occurring in
rural regions that lack resources to purchase drugs for
treatment. Drugs that are currently available have signif-
icant side effects, and treatment regimes are lengthy and
not always transferrable to the field. In consideration of
these factors, new drugs are urgently needed for the
treatment of HAT. To discover compounds suitable for
drug discovery, cultured trypanosomes can be tested
against libraries of compounds to identify candidates for
further biological analysis. We have utilised a 384-well
format, Alamar Blue viability assay to screen a large non-
proprietary compound collection against Trypanosoma
brucei brucei bloodstream form lister 427. The assay was
shown to be reproducible, with reference compounds
exhibiting activity in agreement with previously published
results. Primary screening hits were retested against T.b.
brucei and HEK293 mammalian cells in order to assess
selectivity against the parasite. Selective hits were char-
acterised by chemical analysis, taking into consideration
drug-like properties amenable to further progression.
Priority compounds were tested against a panel of
protozoan parasites, including Trypanosoma brucei rhode-
siense, Trypanosoma cruzi, Leishmania donovani and
Plasmodium falciparum. Five new compound classes were
discovered that are amenable to progression in the drug
discovery process for HAT.
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HMI-9 medium [27], supplemented with 10% fetal calf serum
(FCS) and 100 IU/ml penicillin/streptomycin (Invitrogen, Carls-
bad, California, USA) with incubation at 5% CO2 at 37uC in
humidified conditions. HEK293 cells were maintained in high
glucose DMEM with L-glutamine, supplemented with 16 non-
essential amino acids (NEAA; Invitrogen, USA) and 1 mM sodium
pyruvate. Growth conditions were in 5% CO2 at 37uC, under
humidified conditions.
T.b. brucei Alamar Blue viability estimation assay
All reagent and cell additions were made with a Multidrop
liquid handler (Thermo Scientific, Newington, NH, USA) under
sterile conditions. Fifty-five microliters of 2000 cells/mL of T.b.
brucei in HMI-9 medium were added to a black, clear-bottomed
384-well lidded plate (BD Biosciences, Franklin Lanes, NJ, USA).
Cells were incubated for 24 hours at 37uC in an atmosphere of 5%
CO2 before addition of 5 ml of compounds/DMSO for control
wells. Compounds suspended in 100% DMSO or 100% DMSO
as controls were pre-diluted 1:21 in high glucose DMEM without
FCS by using a Minitrack robotic liquid handler (PerkinElmer,
Waltham, MA, USA). Five microliters of diluted sample was
added to the plate to give a final DMSO concentration of 0.417%
in the assay. Cells were incubated for an additional 48 hours at
37uC. Ten microliters of 70% Alamar Blue (Biosource, Bethesda,
MD, USA) was added to each well (diluted in HMI-9 medium
supplemented with 10% FCS) to a final concentration of 10% in
the assay. The plate was incubated for two hours under the same
conditions, then incubated for 22 hours in the dark at room
temperature. Wells were read at 535 nm (excitation) and 590 nm
(emission) wavelengths on a Victor II Wallac plate reader
(PerkinElmer, USA). Specific dilutions are explained further in
the primary and retest assay methodology. Reference drugs used
in the assay were pentamidine (Sigma-Aldrich, St Louis, MO,
USA), diminazene aceturate (Sigma-Aldrich, USA) and puromy-
cin (Calbiochem, San Deigo, CA, USA). Pentamidine is used to
treat patients with HAT and diminazene is a veterinary drug used
against T.b. brucei to combat infections in cattle. Puromycin is a
non selective, protein synthesis inhibitor.
HEK293 Alamar Blue viability estimation assay
Cells at 80% confluence were harvested and diluted in growth
medium (high glucose DMEM supplemented with 10% FCS) to
7.276104 cells/ml. Under sterile conditions, 55 ml of diluted cells
per well were added to a black, clear bottomed 384- well lidded
plate (BD Biosciences, Bedford, MA, USA) with a Multidrop
liquid handler (Thermo Scientific, Barrington, IL, USA). Incuba-
tion times, compound additions and plate read were as per the
trypanosome viability assay, with the exception that Alamar Blue
was diluted in HEK293 growth media before addition, and
incubation of Alamar Blue at 37uC, in 5% CO2, was for 4 hours,
followed by incubation at room temperature for 20 hours. The
activity of compounds against HEK293 cells was used to calculate
the SI of mammalian to T.b. brucei cells. The control compound for
HEK293 cells was puromycin (Calbiochem, USA).
L6 viability estimation assay
L6 rat skeletal myoblasts [28,29] were purchased from the
American Type Culture Collection (ATCC, Rockville, MD, USA;
ATCC number CRL 1458). This cell line was used for cytotoxicity
testing to calculate an SI against T.b. rhodesiense and screened
alongside the T.b. rhodesiense, P. falciparum, T. cruzi and L. donovani
assays. L6 were also the host cells for the T. cruzi assay. Assays were
performed in 96-well microtiter plates, each well containing 100 ml
of RPMI 1640 medium supplemented with 1% L-glutamine
(200 mM), 10% FCS, and 4000 L6 cells. Serial drug dilutions of
eleven 3-fold dilution steps covering a range from 100 to
0.002 mg/ml were prepared. After 70 hours of incubation the
plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions. Ten ml of resazurin
solution (resazurin, 12.5 mg in 100 ml double-distilled water) was
then added to each well and the plates incubated for another
2 hours. Then the plates were read with a Spectramax Gemini XS
microplate fluorometer (Molecular Devices Cooperation, Sunny-
vale, CA, USA) using an excitation wavelength of 536 nm and an
emission wavelength of 588 nm. Data was analysed using the
microplate reader software Softmax Pro (Molecular Devices,
USA). Podophyllotoxin was used as a positive control in the assay.
T. b. rhodesiense STIB900 assay
T.b. rhodesiense STIB900 stock was isolated in 1982 from a
human patient in Tanzania and after several mouse passages
cloned and adapted to axenic culture conditions [30]. Fifty
microliters of Minimum Essential Medium (MEM) supplemented
with 25 mM HEPES, 1 g/l additional glucose, 1% MEM non-
essential amino acids (1006), 0.2 mM 2-mercaptoethanol, 1 mM
Na-pyruvate and 15% heat inactivated horse serum was added to
each well of a 96-well microtiter plate. Serial drug dilutions of
eleven 3-fold dilution steps covering a range from 100 to
0.002 mg/ml were prepared. Four thousand bloodstream form
cells of T.b. rhodesiense STIB 900 in 50 ml were added to each well
and the plate incubated at 37uC under a 5% CO2 atmosphere for
70 hours. Ten microlitres of resazurin solution (resazurin, 12.5 mg
in 100 ml double-distilled water) was then added to each well and
incubation continued for a further 2–4 hours [31]. Plates were
then read with a Spectramax Gemini XS microplate fluorometer
(Molecular Devices, USA) using an excitation wavelength of
536 nm and an emission wavelength of 588 nm. Data was
analysed using the microplate reader software Softmax Pro
(Molecular Devices, USA). The drug melarsoprol was a positive
control against T.b. rhodesiense.
T. cruzi Tulahuen strain C2C4 b-galactosidase assay
Rat skeletal myoblasts (L6 cells) were seeded in 96-well
microtitre plates at 2000 cells/well in 100 ml RPMI 1640 medium
with 10% FCS and 2 mM l-glutamine. After 24 hours the medium
was removed and replaced by 100 ml per well containing 5000
trypomastigote forms of T. cruzi Tulahuen strain C2C4 containing
the b-galactosidase (Lac Z) gene [32]. After 48 hours the medium
was removed from the wells and replaced by 100 ml fresh medium
with or without a serial drug dilution of eleven 3-fold dilution steps
covering a range from 100 to 0.002 mg/ml. After 96 hours of
incubation the plates were inspected under an inverted microscope
to assure growth of the controls and sterility. Then 50 ml of the
substrate, containing chlorophenol red-b-D-galactopyranoside
(CPRG) and Nonidet, was added to all wells. A colour reaction
developed within 2–6 hours that could be read photometrically at
540 nm. Data were transferred into the graphic programme
Softmax Pro (Molecular Devices, USA), which calculated IC50
values. The drug benznidazole was used as a positive standard in
this assay.
L. donovani axenic amastigote fluorescence assay
Amastigotes of L. donovani strain MHOM/ET/67/L82 were
grown in axenic culture at 37uC in SM medium [33] at pH 5.4
supplemented with 10% heat-inactivated FCS under an atmo-
sphere of 5% CO2 in air. One hundred ml of culture medium
containing 105 amastigotes from axenic culture with or without a
serial drug dilution were seeded in 96-well microtitre plates. Serial
Anti-Proliferative Compounds Trypanosoma.b. brucei
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drug dilutions of eleven 3-fold dilution steps covering a range from
100 to 0.002 mg/ml were prepared. After 70 hours of incubation
the plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions. Ten ml of resazurin
solution (12.5 mg resazurin dissolved in 100 ml distilled water)
[34] were then added to each well and the plates incubated for
another 2 hours. The plates were then read with a Spectramax
Gemini XS microplate fluorometer (Molecular Devices, USA)
using an excitation wavelength of 536 nm and an emission
wavelength of 588 nm. Data was analysed using the software
Softmax Pro (Molecular Devices, USA). Decrease of fluorescence
( = inhibition) was expressed as percentage of the fluorescence of
control cultures and plotted against the drug concentrations. From
the sigmoidal inhibition curves the IC50 values were calculated.
Miltefosine served as a known drug control in this assay.
P. falciparum 3Hypoxanthine assay
In vitro activity against erythrocytic stages of P. falciparum was
determined using a 3H-hypoxanthine incorporation assay [35,36]
using the chloroquine and pyrimethamine resistant K1 strain that
originates from Thailand [37]. Compounds dissolved in DMSO at
10 mg/ml were added to parasite cultures incubated in RPMI
1640 medium without hypoxanthine, supplemented with HEPES
(5.94 g/l), NaHCO3 (2.1 g/l), neomycin (100 U/ml), Albumax
(5 g/l) and washed human A+ red blood cells at 2.5% haematocrit
(0.3% parasitaemia). Serial drug dilutions of eleven 3-fold dilution
steps covering a range from 100 to 0.002 mg/ml were prepared.
The 96-well plates were incubated in a humidified atmosphere at
37uC; 4% CO2, 3% O2, 93% N2. After 48 hours, 50 ml of
3H-
hypoxanthine ( = 0.5 mCi) was added to each well of the plate. The
plates were incubated for a further 24 hours under the same
conditions. The plates were then harvested with a Betaplate cell
harvester (Wallac, Zurich, Switzerland), and the red blood cells
transferred onto a glass fibre filter then washed with distilled water.
The dried filters were inserted into a plastic foil with 10 ml of
scintillation fluid, and counted in a Betaplate liquid scintillation
counter (Wallac, Zurich, Switzerland). IC50 values were calculated
from sigmoidal inhibition curves using Microsoft Excel. Chloro-
quine was used as a positive control in the hypoxanthine assay.
Primary screening campaign
Primary screening of the library, consisting of 87,296 com-
pounds in two hundred and forty eight 384-well plates, was
undertaken in single point against T.b. brucei. Stock solutions
consisted of test compound at a concentration of 5 mM in 100%
DMSO. One ml of each compound stock solution was diluted by
the addition of 40 ml of dilution medium (high glucose DMEM
without FCS) by a multidrop liquid handler (Thermo Scientific,
USA). A 5 ml sample of this diluted solution was then added to the
trypanosome assay plate. The final concentration of test
compound in the assay was 10.2 mM and that of DMSO was
0.42% v/v. Compounds were screened over a total of 11 days, at
an average of 80 plates per day, taking into consideration that the
assay incubation was 3 days total. Test compounds were added to
plates in batches of 20 at two hour intervals, to maintain the timing
of additions and reads.
Compound activity was calculated as the percentage inhibition
in relation to positive and negative controls. The positive control,
pentamidine, was contained in whole control plates, separate to
the plates containing compounds, and the negative control (no
effect) comprised of 0.42% DMSO, in column 24 of each test
compound assay plate. These in-plate negative controls were used
in an effort to normalise compound activity in relation to any plate
to plate variation in the assay signal. A whole 384-well control
plate was included in each day’s screening, one per 20 compound
plates containing half a plate of 2 mM pentamidine for the positive
assay control, and half a plate of 0.42% v/v DMSO as a negative
control. The positive assay control was used to calculate
compound activity for batches of 20 compound plates. As well
providing the positive control data, these whole plate controls were
used for the calculation of the Z’ to measure the reproducibility of
the assay. An active hit was defined as a compound that
demonstrated greater than the mean percentage activity of the
library, plus three times the standard deviation. A separate plate
containing a 13 point dose-response of reference compounds in
triplicate was also included per 20 test plates to calculate the
sensitivity of the assay.
Retest library screening hits
Compounds identified from primary screening were retested
against both T.b. brucei and HEK293 cells in duplicate and at
varying concentrations to obtain a dose-response curve. Thus, a
5 ml sample of fresh compound stock solution (5 mM in DMSO)
was cherry picked into 384-well plates and diluted 1:10 in dilution
medium (high glucose DMEM without FCS). Serial dilutions of
these samples were then prepared in the same media by a Minitrak
robotic liquid handler (Perkin Elmer, USA). This resulted in a total
13 doses per sample with 41.7 mM as the highest concentration of
test compound, for which the DMSO concentration was 0.83% v/
v. A screening dose of 10.4 mM was included in the dilution series
to enable reconfirmation of primary screening T.b. brucei activity.
Compounds with activity against T.b. brucei #10 mM, which also
displayed an SI of $10, were selected for medicinal chemistry
analysis.
The DMSO working concentration in the serial dilutions was
maintained at 5%, giving a final assay concentration of 0.42%
DMSO, except for the 41.7 mM test compound solution, where as
previously stated the corresponding DMSO concentration was
0.83% v/v. The concentration of DMSO that can be tolerated in
the T.b. brucei assay has been previously determined as 0.42% [20].
Therefore the 41.7 mM test compound sample with 0.83% v/v
DMSO was not used in the T.b. brucei assay and thus the top test
compound concentration in this assay was 20.8 mM. However, as
the HEK293 assay can tolerate 0.83% DMSO (results not shown)
the highest test compound concentration of 41.7 mM with 0.83%
DMSO was included in the HEK293 assay in order to maximise
the chances of deriving an IC50 value for more weakly cytotoxic
compounds.
Compound activity in the retest campaign was calculated as
percentage inhibition in relation to positive and negative controls,
in the same manner as the primary screening campaign. The
positive controls, pentamidine (2 mM final concentration) for T.b.
brucei and puromycin (8 mM final concentration) for HEK293,
were both screened in whole 384-well control plates. Whole 384-
well plate controls were included after every batch of 20
compound plates, and were comprised of half a plate of negative
control and half a plate of positive control. The negative control
was the vehicle, 0.42 mM DMSO. The negative control was also
included in column 24 of each compound assay plate to
determine signal variation from plate to plate and to calculate
compound activity. The exception was the 41.7 mM compound
dose used in the HEK293 assay. In these plates column 24
contained 0.83% DMSO as a negative control. A separate 384-
well plate containing a 13 point dose-response of the reference
compounds puromycin, pentamidine and diminazene, in tripli-
cate, was also included per 20 compound test plate batch to
estimate assay sensitivity.
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Medicinal chemistry analysis of retest actives
Cluster analysis of the active compounds (n = 205) identified and
confirmed from the primary and follow up retest campaign was
performed using Pipeline Pilot. A predefined functional class
fingerprinting set (FCFP_6, average number of molecules per
cluster = 5, max distance to center = 0.6) was applied, followed by
the removal of compounds carrying toxicophores (n = 35) or
permanent charge (n = 25) based on filters developed in-house,
which include a list of 110 undesirable chemical moieties. The
remaining clusters (n = 93, total of 137 compounds) were then
independently scored by 3 medicinal chemists with industrial
experience. Scoring was based on criteria including activity and
selectivity, number of active analogues in the cluster, drug-like
structural features, chemical tractability, presence of additional
toxicophores not detected by the previously applied filters,
potential for CNS penetration, and possible overlap with scaffolds
already considered for HAT development at DNDi, or the
literature.
Compound resupply and quality control (QC)
Following medicinal chemistry analysis, compounds deemed to
be of most interest were re-purchased or re-synthesised and
analysed by liquid chromatography-mass spectrophotometry
(LCMS) to confirm expected molecular weight and acceptable
purity (.85%) prior to retesting of biological activity. These
compounds were retested as in dose for N of three replicates, as
described above for both T.b. brucei and HEK293.
SAR mining: structure activity analysis of hit compounds
For SAR mining, hit compounds were compared structurally to
the whole primary screening compound collection. A series of
substructure searches, performed in ActivityBase, were defined
and refined to retrieve analogues most relevant to SAR
interpretation. We have undertaken SAR mining for more than
60 HTS campaigns and have found substructure searching to
return more meaningful SAR-relevant analogues than similarity
searching. This is not surprising as it is well known that
fingerprint-derived structural recognition captures medicinal
chemistry-based structural recognition in only a rudimentary
fashion [38]. The substructures that were used for searches are
shown in Figure 1. A1 and A2 were the basis for searches for
analogues of compounds 1 and 2, B1–B3 were used for compound
3, C1 for compound 6, D1 for compound 8, and E1–E3 for
compound 7.
Determination of the cidal action of compounds
For compounds 1, 2, 6 and 7, the minimum inhibitory
concentration (MIC) was determined from a concentration
response curve, generated using the Alamar Blue assay. The
MIC was extrapolated as the minimum concentration at which
there was a plateau of activity in the assay (.95% activity). For
compound 1, this was 3.97 mM, compound 2 was 19.8 mM,
compound 6 was 9.92 mM and compound 7 had a MIC of
0.99 mM. To determine cell counts at this MIC, compounds at
their MIC concentration were added following incubation of
26103 parasites per well for 24 hours in the absence of
compound. Cell numbers were determined after 24, 48 and
72 hours exposure to compounds and compared to controls of
puromycin, also at an MIC concentration (1.15 mM). Puromycin
was used as a positive control for 100% cell death (cidal action),
as since for this drug there were no parasites remaining in the
treated wells following 24 hours. The MIC calculated for
pentamidine was 0.04 mM.
Time to kill assay
IC50 values were determined for compounds 1, 2, 6 and 7
following exposure of T.b. brucei to each compound for 29, 48 and
72 hours. The starting dose was 40 mM, and the IC50 values were
determined from a 16 point dose-response curve. The assay
conditions were the same as previously described for the Alamar
Blue assay, except that 10 mL of a final 10% concentration of
Presto Blue in HMI-9 medium was added as the indicator of
viable cells, at various time points. At the first time point,
following 20 hours of incubation with compounds, Presto Blue
was added to the wells and incubation at 37uC continued. Plates
were read every hour and returned to continue incubation at
37uC. This was performed to determine at which time point there
was a reproducible signal (Z’ of .0.5), using puromycin as a
negative control and 0.42% DMSO as a positive control. This
corresponded to a 9 hour incubation, or 29 hours incubation in
the presence of the compound. After 45 hours incubation, Presto
Blue reagent was added, and the samples incubated for an
additional 3 hours, thus read at 48 hours to give a reproducible
signal. Similarly, at 70 hours, reagent was added, samples
incubated for another 2 hours and read at 72 hours. If a
compound reached a plateau of activity and no cells were
identified at the MIC, compounds were considered to have been
effectively cidal at that time point.
Results
Primary screening campaign
As a hit threshold, three times the standard deviation plus the
mean of the activity of the compound collection was calculated at
50%, in an effort to reduce false positives in the assay. Compounds
with $50% activity were therefore considered active. From the
primary screening campaign, 1,980 compounds inhibited T.b.
brucei growth by $50%, a hit rate of 2.27%. These were grouped
into two classifications, the first containing those compounds that
inhibited growth between $50% and ,80% and the second
consisted of compounds with inhibitory activity of $80%. Group
two was comprised of 1,217 compounds and it was these that were
progressed to initial retesting. In-plate controls revealed little
variation in the assay signal expressed as a ratio of maximum
signal to background, throughout the entire test period (Figure 2).
From separate whole plate controls, the Z’ was calculated as an
average of 0.8160.05 (Figure 3). IC50 values for each of the
reference compounds determined over the four screening days are
shown in Figure 4. For each screening day, there were four control
plates containing a dose-response of each reference compound, in
triplicate, starting at doses of: puromycin 120 mM, pentamidine
70 mM and diminazene 80 mM. One control plate was included
for screening per 20 compound plate batch. Thus, there were 4
control plates each in the first 3 days of screening (80 library
compound plates per day) and only 1 control plate for the last (8
library compound plates). Mean IC50 values and standard
deviations were therefore calculated from 12 replicates each on
days 1–3, and 3 replicates of dose-response of reference
compounds on day 4. These values were not significantly different
from one another, as determined by a one way ANOVA in
GraphPad Prism, with a significant difference of P,0.05. An IC50
value was not considered reproducible if varying more than 3
times from the mean. All values fell within three times the mean.
IC50 values for the reference compounds were 61.966.8 nM for
puromycin, 65.4 nM612.5 nM for diminazene and 14.764.7 nM
for pentamidine.
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Retest screening campaign
Of the 1,217 primary actives that were retested from stock
solutions in duplicate with dose-response curves, 822 compounds
(67.5%) reconfirmed in duplicate to be $50% inhibitory in the
T.b. brucei assay at the serial dilution concentration point of
10.4 mM (closest to the primary screening concentration of
10.2 mM). A dose-response plateau is necessary for IC50 values to
be determined for these compounds. Hence, a compound
needed to display $80% inhibitory at both 41.7 mM and
20.8 mM in duplicate (although one singleton was allowed to
extend to $70%). There were 57.6% of the 1,217 compounds
that passed these criteria. For all these compounds, titration data
were imported into GraphPad Prism and the IC50 values
estimated.
Figure 1. The refined substructures used for SAR mining of prioritised compounds. Parent compounds (with substructures used in the
search for each) were: compounds 1–2 (A1–A2); compound 3 (B1–B3); compound 6 (D1); compound 8 (E1); compound 7 (E1–E3). In the substructures,
‘‘A’’ = any atom except for H. All hydrogens are made explicit.
doi:10.1371/journal.pntd.0001896.g001
Anti-Proliferative Compounds Trypanosoma.b. brucei
PLOS Neglected Tropical Diseases | www.plosntds.org 6 November 2012 | Volume 6 | Issue 11 | e1896
Similarly for the HEK293 assay, only data whereby an IC50
value could be estimated were imported in to GraphPad Prism.
There were 700 compounds that displayed $80% inhibition at
both 41.7 mM and 20.8 mM in duplicate (although one singleton
was allowed to extend to $70%). As before, criteria included a
plateau of activity necessary for the calculation of an IC50 value.
The HEK293 IC50 value could be estimated for 10% of the 700
compounds in this manner and this allowed for the determination
of the SI. For the remainder of compounds, an estimation of the
IC50 against HEK293 cells was possible by observing the lowest
concentration in the HEK293 assay that displayed $50%
inhibition in at least one of the two replicates.
Using these analyses, there were 205 (29%) of the 700 re-
confirmed compounds that had an estimated SI of $10. Of these
compounds, 8 produced a non-sigmoidal curve in the T.b. brucei
assay and therefore could not have an IC50 value, nor SI
estimated. This may have been due to compound solubility, or the
nature of the compound’s action, and these compounds were de-
prioritised. This left 197 hits that were progressed to medicinal
chemistry cluster analysis.
Control plates, used as a measure of reproducibility, showed
that the T.b. brucei assay had an average Z’ of 0.74 (Figure 3). For
the HEK293 assay, the mean Z’ was 0.73 for both 0.42% DMSO
and 0.83% DMSO final assay concentrations. Puromycin was
active on both cell lines with an IC50 of 138.5615.7 nM against
T.b. brucei and 11236155 nM against HEK293. Puromycin, a
known cytotoxic compound therefore exhibited an SI of less than
10, supporting the use of the Alamar Blue for the identification of
cytotoxic compounds. For T.b. brucei, diminazene exhibited an
IC50 value of 29.565.8 nM and pentamidine 7.863.6 nM.
Figure 2. Signal window in the T.b. brucei primary screening campaign. The signal window for each of 248 plates containing test compounds
in the primary screening campaign, expressed as a ratio of the negative to positive controls. Each dot represents the signal window calculated for a
single plate. Control plates, one per 20 test compound plates, contained half a 384-well plate of 2 mM of the positive control compound,
pentamidine. Negative assay controls, of 0.42% DMSO, were contained in column 24 of each assay plate containing test compounds, or 16 wells in
total. The signal window was based on the average of column 24, divided by the average of the positive control taken from the control plate.
doi:10.1371/journal.pntd.0001896.g002
Figure 3. Signal and reproducibility of negative and positive controls in the T.b. brucei primary and retest assays. The negative and
positive control assay signals (fluorescence intensity, left Y-axis) taken from whole control plates (one per 20 test compound plates) in the primary
screening (A) and retest (B) screening campaigns. Negative controls were averaged from wells containing 0.42% DMSO and positive controls were
from wells containing 2 mM pentamidine. The bar plots show the Z’-factor (Z’, right Y-axis) for each control plate, a measure of the reproducibility of
the controls in the assay.
doi:10.1371/journal.pntd.0001896.g003
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Neither pentamidine nor diminazene displayed activity in the
HEK293 assay at the doses screened (1 mM and 40 mM,
respectively).
Medicinal chemistry analysis of retest actives
Scoring was attributed independently by 3 medicinal chemists
with industrial experience and was based on criteria including
criterion 1: activity and selectivity (compounds with IC50 values
indicating good activity and high selectivity were favored); criterion
2: number of active analogues in the cluster (cluster with n.1 were
preferred to singletons), criterion 3: drug-like structural features
(based on Lipinski’s rule of 5 scoring [39]), criterion 4: chemical
tractability (based on personal experience, as well as availability of
commercial analogs), criterion 5: presence of additional toxico-
phores not detected by the previously applied filters (personal
experience), criterion 6: potential for CNS penetration such as
molecules with low PSA, low molecular weight, low clogP and low
number of H-bond donor/acceptors [40]. It is recognised that this
method is internally consistent, however may differ from analysis
undertaken by other medicinal chemists [41]. This analysis lead to
the selection of 11 compounds for retesting.
Re-synthesis and rescreening of compounds
The 11 compounds identified from medicinal chemistry analysis
were either re-synthesised or re-purchased, and re-tested in both the
T.b. brucei and HEK293 assays. Following this, the number was
reduced to 8 (Table 1) after two resupplied compounds did not
confirm activity in the T.b. brucei assay (,50% activity, results not
shown). A third compound was found to only be.50% active at the
top dose of 65 mM and therefore was unsuitable for IC50 or SI
calculation. The IC50 values and calculated selectivity indices of the
remaining 8 compounds are outlined in Table 1, and the structures
in Figure 5. During rescreening of resynthesized compounds the Z’
for the T.b. brucei assay was 0.8160.02 and 0.8860.01 for the
HEK293 assay. In the T.b. brucei assay, pentamidine displayed an
IC50 value of 3.5260.36 nM, diminazene 12169.04 nM and
puromycin 58.460.77 nM (Table 1). In the HEK293 assay,
puromycin was active at 518628.1 nM, whilst as expected neither
pentamidine nor diminazene displayed activity at the doses
screened (1 mM and 40 mM, respectively). The selectivity index
for puromycin was similar to that found at original retest, (8.9 fold,
Table 1), as expected for a non-selective inhibitor.
Screening against related protozoal species
The compounds identified by medicinal chemistry analysis as
the most promising were also tested in dose-response against the
human infective parasites T.b. rhodesiense, L. donovani and T. cruzi to
estimate IC50 values. Data obtained is shown in Table 1. Rat
skeletal L6 muscle cells were also used as an indicator of
cytotoxicity and the SI was calculated against all species. Initial
analysis of compound activity was made against the HAT
reference strain, T.b. rhodesiense, taking into consideration the
IC50 value and the SI. Criteria used were as described for the
primary screening and retest campaigns, therefore for compounds
to be initially considered as favourable hits for further progression,
the IC50 cut off was,10 mM and the SI.10. Compound 5 had an
IC50 value ,10 mM and a corresponding SI of ,10, and thus was
de-prioritised. Compound 4 displayed an SI of 0.19 and therefore
was also de-prioritised. This left a panel of 6 compounds to be
considered for further progression. Table 2 shows the physio-
chemical properties of these 6 prioritised compounds: the
molecular weight, aqueous solubility, polar surface area and
cLogP.
Reference compounds were used as controls throughout testing
with all of these assays and are also shown in Table 1. For the T.b.
rhodesiense assay, the drug melarsoprol displayed an IC50 of
6.2861.78 nM. Benznidazole, a drug used to treat Chagas
disease, was 168061930 nM active and miltefosine, a treatment
for Leishmaniasis had an IC50 value of 365693.7 nM. The drug
chloroquine was active against P. falciparum with an IC50 of
164624.7 nM.
SAR mining: structure activity analysis of hit compounds
For the 6 hit compounds, ActivityBase was used for
substructure searching to identify the relevant analogues to
associate with the primary screening data. The refined
substructures used for searches are shown in Figure 1. Tables
S1, S2, S3 and S4 show structure and activities of these
compounds over the T.b. brucei primary screening and retest
campaigns. Identified analogues are shown in Supplementary
Table S1 (compounds 1 and 2), Table S2 (compound 3), Table
S3 (compound 6) and Table S4 shows analogues of compound 7.
No analogues of compound 8 were found in the library using
these methods, even using the relatively broad substructure
definition D1 in Figure 1.
Figure 4. Reference compound activity against T.b. brucei in the primary screening campaign. Dose-response curves for the reference
compounds pentamidine, puromycin and diminazene against T.b. brucei in the primary screening campaign. Means and standard deviations of
replicate IC50 values were (A) pentamidine, 14.764.7 nM (B) puromycin, 61.8666.8 nM and (C) diminazene, 65.4 nM612.5 nM. Data is representative
of 13 control plates each containing 3 replicates of the compounds in dose, with batches indicative of daily screens.
doi:10.1371/journal.pntd.0001896.g004
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Determination of the cidal action of compounds
Measurements of the number of T.b. brucei cells, following
exposure to the MIC of compounds 1, 2, 6 and 7 during a 72 hour
period, are shown in Figure 6. Treatment with three of the 4
compounds at the MIC for 24 hours resulted in cell counts
indicating the complete lack of viable trypanosomes. However, the
compound pyrido-isoxazol-2-ylanilide (compound 7), only cleared
parasites following 72 hours incubation. At the MIC of puromy-
cin, no cells remained following 24 hours treatment, whereas with
pentamidine this effect was not observed until 72 hours incubation
at the MIC.
Time to kill assay
The IC50 values for all 4 compounds selected for cidal
assessment did not differ between the Presto Blue assay at
72 hours and the Alamar Blue assay (total compound exposure
in this assay is also 72 hours), as shown in Table 3. Thus the
Presto Blue assay was considered to also be an accurate indicator
of compound activity measured over time and the results were
comparable to IC50 values determined in the Alamar Blue assay.
All compounds were active at 29 hours, with a plateau of activity
displayed in dose-response curves. Compounds 1, 2 and 7
showed similar IC50 value across all time points, while
compound 6 reached a stable IC50 value at 48 hours incubation
with the compound (Table 3). Puromycin and pentamidine were
demonstrated to reach a maximum IC50 value after 48 hours
exposure.
Discussion
Due to the many problems associated with current existing
treatments for HAT, in particular toxicity, treatment regimes
and cost, there exists a tangible need for new compounds to be
introduced into early HAT drug discovery. HTS has been
utilised by a number of research groups for HAT to identify
active compounds for the drug discovery process, however there
are few incorporating the use, or development of HTS for whole
cells [20,42,43]. The inclusion of an assay to estimate cytotox-
icity as a part of a whole cell HTS campaign is an important
Table 1. Activity of re-isolated compounds identified from the T.b. brucei primary and retest campaigns.
Compound activity (mM) Selectivity Index
Compound1 T.B (Hill Slope) T.R L.D P.F T.C T.B2 T.R3 L.D3 P.F3 T.C3
1 0.78560.0829
(3.89)
1.4760.390 46.1622.4 35.462.75 2.3260.0601 .96.0 42.3 1.35 1.76 26.8
2 4.0060.0555
(17.0)
6.7760.545 47.360.324 23.968.48 19.360.0905 .19.0 17.6 2.53 5.00 6.20
3 1.1360.347
(3.21)
0.85460.332 16.161.70 14.366.64 19.165.32 .67.1 58.5 3.09 3.48 2.56
4 3.0860.290
(3.33)
4.8562.08 0.48860.154 8.1764.00 15.464.29 24.6 0.186 1.84 0.110 0.0588
5 2.1160.130
(3.09)
14.460.0995 6.6061.56 12.6265.87 14.7660.151 .35.9 1.51 3.29 1.72 1.47
6 1.1660.304
(0.785)
0.96760.450 34.065.60 11.3364.79 19.165.32 .65.3 18.4 0.525 1.58 0.933
7 0.21860.00714
(6.80)
0.58660.073 1.8260.277 7.7663.22 0.23060.0496 .344 38.4 12.5 2.92 98.6
8 2.6160.320
(3.03)
0.87560.065 .263 5.3362.04 82.161.69 .29.0 150 NA 24.8 1.61
Reference Compound Reference Compound Activity (nM)
Puromycin 58.460.769
(4.90)
8.90
Pentamidine 3.5260.360
(1.65)
.283
Diminazene 12169.04
(4.25)
.330
Melarsoprol 6.2861.78 2915
Miltefosine 365693.7 392
Chloroquine 164624.7 507
Benznidazole 168061930 .206
Species names are abbreviated. T.B = T.b. brucei; T.R = T.b rhodesiense; L.D = L. donovani; P.F = P. falciparum; T.C = T. cruzi.
NA is not applicable as the IC50 value could not be determined within the dose range.
(1)Compound numbers refer to those outlined in Figure 4.
(2) SI was calculated with relative IC50 values of T.b. brucei and HEK293 cells. Value is described as ‘‘.’’ if the compound exhibited less than 50% activity at the top dose
screened in the HEK293 assay at 75.8 mM, therefore an IC50 could not be estimated.
(3)SI was calculated with relative IC50 values of T.b. rhodesiense, L. donovani, P. falciparum and T. cruzi to L6 cells.
The standard deviation was calculated from two experiments with one replicate in each for the T. cruzi, L. donovani and P. falciparum assays and from three experiments
containing two replicates each for the T.b. brucei assay.
Compound activity against T. b. brucei and a panel of human infective protozoal species, including the HAT species T.b. rhodesiense of compounds identified from the T.
b. brucei screening campaign. These compounds had the most favourable overall biological and medicinal chemistry profiles.
doi:10.1371/journal.pntd.0001896.t001
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consideration for the progression of potential compounds. Here
we describe the utilisation of an Alamar Blue HTS assay [20] to
successfully screen a library of almost 90,000 small molecules.
Following medicinal chemistry analysis of the positive hits in the
assay, eight compounds with activity against T.b. brucei were
identified. These compounds had IC50 values ranging from
0.22 mM to 4 mM with associated selectivity indices ranging from
19 to greater than 345.
Both the primary and retest screening campaigns were
reproducible as exemplified by the statistical coefficient of the
Z’. For the primary screening campaign, the Z’ was averaged at
0.81 for the T.b. brucei assay (Figure 3). At retest the respective Z’
Figure 5. Priority hit compounds with activity against T.b. brucei and T.b. rhodesiense. Compound class and compound structures of the 6
priority hits identified from the T.b.brucei screening campaign, following screening against other protozoal species, medicinal chemistry analysis and
consideration of optimal physiochemical properties.
doi:10.1371/journal.pntd.0001896.g005
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values were 0.74 and 0.73 for T.b. brucei and HEK293 assays.
Throughout the campaign, reference compounds in the T.b. brucei
assay were within the range of the IC50 value of previously
reported results for the same assay format [20]. The reproduc-
ibility of the reference compounds over primary screening days is
highlighted in Figure 4. The HEK293 assay was validated in this
campaign as effective for the identification of cytotoxic compounds
by the activity of the compound puromycin. Puromycin is a
general cell growth inhibitor of both eukaryotic and prokaryotic
cells which disrupts protein synthesis. It was active on both cell
lines in the retest screening campaign with an IC50 of
138.5615.7 nM against T.b. brucei and 11236155 nM against
HEK293. This compound would therefore have been correctly
identified as non-specifically cytotoxic by our criteria that a
potentially useful T.b. brucei active must have an initial SI .10.
This was also shown through the data obtained for the controls
from during screening of re-isolated compounds, where the SI for
puromycin was 8.9 (Table 1). As anticipated, neither pentamidine
nor diminazene, which are registered drugs against HAT and T.b.
brucei, respectively, exhibited activity in the HEK293 assay at the
doses screened. Diminazene is reported to have an SI of 692 [44],
whilst pentamidine has low mM activity reported for some
mammalian cell lines [45].
The 8 compounds identified following reconfirmation of actives
from new solids and chemical clustering were subjected to testing
against the human HAT infective species T.b. rhodesiense, as well as
other protozoal species that cause disease such as T. cruzi (Chagas
disease), L. donovani (Leishmaniasis) and a chloroquine and
pyrimethamine resistant strain of P. falciparum (Malaria). The
structures and chemical classes of these compounds, designated
compounds 1 to 8, are shown in Figure 5. As an additional
mammalian cytotoxicity control and one relevant when screening
these additional assays for protozoal parasites, the rat skeletal
myoblast L6 cell line was used as this cell line is the host cell line
used for the T. cruzi assay. The biological activities of these 8
compounds against T.b. brucei, a panel of human infective parasite
species, plus the L6 cytoxicity data, with corresponding HEK293
selectivity indices are shown in Table 1. The activity of the
relevant control/reference drugs has also been included. On the
basis of this data, 2 compounds displayed relatively low (Table 1,
compound 5) or extremely low (Table 1, compound 4) SI and thus
were not considered favourable for progression. This left 6 high
priority compounds, representing 5 distinct structural classes that
could serve as a basis for progression in the early drug discovery
process for HAT. Structures and key physicochemical properties
for selected compounds are listed in Table 2. For analysis of
physicochemical properties, a cLogP of 1–4 is considered
favorable; .4–6 is acceptable, while .6 is unfavorable. A
preferred solubility is considered to be .10 mM. Polar surface
area is considered to be good at less than 70 A˚2 and acceptable less
than 80 A˚2. A molecular weight lower than 400 is preferred in
terms of lead-likeness and blood brain barrier crossing properties.
The phenylthiazole amide (compound 1) was active against T.b.
brucei with an IC50 value of 0.79 mM and an SI of .96. It was
similarly active against T.b. rhodesiense with an IC50 of 1.5 mM and
an SI of 42. This compound also demonstrated activity against T.
cruzi with an IC50 of 2.3 mM. In terms of physicochemical
properties, it has a low molecular weight of 306, predicted good
aqueous solubility of 63 mM, a low polar surface area of 42 A˚2
suitable for CNS penetration, and a favourable cLogP of 3.4.
Figure 6. Determination of the cidal activity of compounds 1, 2, 6 and 7 over 72 hours. Death of T.b. brucei cells in wells estimated by
parasite counts at 24, 48 and 72 hours following addition of the minimum inhibitory concentration (MIC) of each compound. The positive control was
puromycin.
doi:10.1371/journal.pntd.0001896.g006
Table 2. Physicochemical properties of the top 6 hit compounds.
Compound1 mw Calculated aqueous solubility (mM) Polar Surface Area (A2) cLogP
1 306 63 42 3.4
2 328 8 71 2.9
3 353 25 39 4.8
6 270 3,160 81 2.0
7 339.5 0.025 81 2.6
8 380 32 67 3.1
1Compound numbers refer to those outlined in Figure 5.
doi:10.1371/journal.pntd.0001896.t002
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Phenyltriazol-5-yl-ethylamide (compound 2), although closely
related, was significantly less active against T.b. brucei with an
IC50 value of 4.0 mM, with also a weaker T.b. rhodesiense activity
IC50 of 6.8 mM. The SI for compound 2 determined against both
HEK293 and L6 cells was approximately 20. The physicochem-
ical properties of this compound reveal it to be of low molecular
weight, with an acceptably low polar surface area of 71 A˚2 and a
favourable cLogP of 2.9, although the calculated aqueous
solubility is low at 8 mM. A literature search revealed no
biologically active compounds closely related to these two hit
compounds, suggesting that these compounds may represent
starting points for novel trypanocides. There were approximately 3
dozen compounds related to compound 1 (Table S1), approxi-
mately two dozen of which (1, 4–7, 16–24, 26–28, 33–36) were
structurally very similar. Few of these exhibited any activity,
suggesting tight SAR around the core structure. The exception to
this was the potent thiophene-containing compound (entry 23),
that did not initially pass the medicinal chemistry functional group
filters, because of the thiophene group. However, this compound
still provides useful SAR and suggests that different hydrophobic
amides may be tolerated in this region with retention of potent
activity. Remaining compounds were more distant, conformation-
ally constrained, or contained heterocyclic alternatives to the
thiazole and none were active.
The phenoxymethylbenzamide (compound 3) had moderate
activity against T.b. brucei with a retest IC50 of 1.1 mM and an SI of
.67. It was similarly active against T.b. rhodesiense with an IC50 of
0.85 mM and an SI of 60. In terms of physicochemical parameters,
this compound has a moderately low molecular weight of 353, a
calculated aqueous solubility of 25 mM, a low polar surface area of
39 A˚2 and an acceptable cLogP of 4.8. SAR mining revealed 34
analogues related to compound 3 (Table S2). Some of these
compounds had only relatively minor changes (entries 5, 11, 13,
33) but of these, only one (entry 13) showed some activity (77% at
10.4 mM), suggesting both ends of the molecule (piperidine amide
and p-alkoxyphenyl) are likely to be important for activity. The
remaining compounds tended to have more significant changes to
both ends or the central unit and none of these were active except
for one (entry 3), suggesting the piperidine could be replaced with
a diaminoethane though cytotoxicity would need to be monitored.
The activity of the pyrimidin-2-yl-pyrazol-5-ylamide (com-
pound 4) was 3.1 mM for T.b. brucei, with an SI of 25. This
compound also demonstrated activity against T.b. rhodesiense IC50
of 4.8 mM but with an extremely low SI of 0.19 to L6 cells, and it
was for this reason that this compound was not included in the top
6 compounds to be considered further. The 7-aminotetrahydro-
quinoline bis sulfonamide (compound 5) had a moderate retest
T.b. brucei IC50 value of 2.1 mM and an SI of 36 to HEK293 cells.
However the low activity observed against the infective species
(T.b. rhodesiense) of 14 mM rendered this compound de-prioritised.
None of the entries 1, 2, 3 or 5 belong to classes associated with
any known biological activities as far as the authors can ascertain.
However, this is not the case for compound 6, 6-aryl-3-aminopyr-
azine-2-carboxamide, which was moderately active with a retest
IC50 of 1.2 mM and an SI of.65 when cytotoxicity is measured on
HEK293 cells. It was similarly active against T.b. rhodesiense with an
IC50 of 0.97 mM and an SI to L6 cells of 18. This compound is
predicted to have a favourable aqueous solubility of 3.2 mM, has a
low molecular weight of 270, an acceptably low polar surface area of
81 A˚2 and a favorable cLogP of 2.0. This class is quite heavily
patented and associated with numerous biological activities [46–
50]. Only one compound was a close analogue of compound 6, a
des-N-alkyl carboxamide (Table S3), however this was inactive,
suggesting the alkyl group is essential for activity.
The pyrido-isooxazol-2-ylanilide (compound 7) is an isoxazol-2-
ylanilide with a fused pyridine ring and displays the best biological
activity profile of all compounds, with a T.b. brucei retest IC50 value of
0.22 mM and an SI of .345. It was similarly active against T.b.
rhodesiense with an IC50 of 0.59 mM and an SI of 39. This compound
also displayed activity against T. cruzi with an IC50 of 0.23 mM and
an IC50 against L. donovani of 1.8 mM, suggesting potential as a broad
spectrum anti-kinetoplastid. The physicochemical properties of this
compound are favourable, with a moderately low molecular weight,
an acceptable polar surface area of 81 A˚2 and a favourable cLogP of
2.6. The calculated aqueous solubility is low (25 nM) and it is possible
the actual solubility may be improved due to the ortho effect of the 2-
chloro substituent. This compound belongs to a class with an isolated
report of biological activity, activation of the NAD+-dependent
deacetylase SIRT1 [51], a sirtuin, which also appears to be present
and important in trypanosomes [52–54]. This compound would
appear to present a promising starting point for drug development,
though early investigation of aqueous solubility and its improvement
could be important. For this compound, there were 19 analogues
that provided useful SAR (Table S4). Several compounds suggested
the furan was important for activity, as replacement with substituted
phenyl ring (entries 6, 10, 11, 16, 17, 19) or extension (entries 5, 7, 9,
12, 15, 18) led to inactive compounds. However, replacement with a
simple propyl group (2) led to an active compound suggesting smaller
hydrophobics may be acceptable. Two compounds had small
changes in other parts of the molecule and were also inactive,
suggesting even simple substitution changes to the central phenyl
ring (entry 3) are not necessarily tolerated nor small changes to the
distal pyridine ring (entry 4). While more significant in their
alterations, all other analogues are still clearly related to the parent
compound yet inactive, suggesting tight SAR.
The aminoethyl benzoyl arylguanidine (compound 8) displayed
a T.b. brucei retest IC50 value of 2.6 mM and an SI of .29. This
compound displayed increased activity against T.b. rhodesiense with
an IC50 value of 0.88 mM and an SI of 150, whereas the activity
against T. cruzi was low (IC50 of 82 mM). The biologically active
conformation of this molecule may adopt an intra-molecular
hydrogen-bonded form as shown [55], similar to benzoylureas
[56]. In terms of physicochemical properties, this compound has a
moderate molecular weight of 380, a reasonable aqueous solubility
of 32 mM, an acceptably low polar surface area of 67 A˚2 and a
favorable cLogP of 3.1. Closely related compounds are patented as
Table 3. Time to kill estimated by the IC50 values of
compounds 1, 2, 6 and 7 over 72 hours.
Compound1 Activity (nM IC50 value)
29 hours 48 hours 72 hours AB1 assay
1 8986332 691666.4 1030618.4 1100665.1
2 48406449 38306873 500643.1 47106272
6 309061380 177611.0 111650.2 160640.3
7 17867.00 142638.7 220617.6 19861.28
Puromycin 152665.4 58.1610.1 68.660.283 64.160.240
Pentamidine 9.1362.76 3.4160.661 4.6660.936 5.8160.707
The IC50 values for each compound were determined at 29, 48 and 72 hours
following the addition of compound by a Presto Blue-based assay, over 2
experiments. The IC50 was also determined for the Alamar Blue-based HTS assay
format. The positive control was puromycin and the reference compounds were
puromycin and pentamidine.
1Compound numbers refer to those outlined in Figure 5.
doi:10.1371/journal.pntd.0001896.t003
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inhibitors of human mitochondrial F1Fo- ATPase [57], the same
molecular target that DB289 has been suggested to target in T.
brucei [58]. Oligomycin A, which is known to inhibit mitochondrial
membrane associated ATPases in mammalian cells [59] has also
demonstrated potent activity against T.b. brucei [60]. Oligomycin
sensitive ATPases have been found to be present in T.b. brucei [61].
The aminoethyl benzoyl arylguanidine represents a highly
tractable and attractive structure for medicinal chemistry optimi-
zation, although consideration will need to be given to the
potential for liver toxicity manifested in DB289, and how this may
be overcome [9]. Data mining showed there were no analogues of
this compound in the library screened.
From the hit chemical classes, compounds 1, 2, 6 and 7
underwent further biological profiling to ascertain whether their
action was cidal or static at the MIC determined. Of the 4
compounds profiled, all had completely cleared parasites in wells
by 72 hours incubation at the MIC (Figure 6) and were therefore
considered to have a cidal action. Compounds 1, 2 and 6 and the
control puromycin resulted in complete depletion of trypanosomes
at this dose at 24 hours, whilst compound 7 and the control
compound, pentamidine, required a 72 hour incubation to attain
the same effect.
To determine the IC50 values of compounds 1, 2, 6 and 7 over
time, as an estimation of the kill time, the resazurin-based reagent,
Presto Blue, was used. In the presence of live cells this dye converts
more rapidly to a fluorescent end product, in comparison to
Alamar Blue (results not shown). Dose-response curves of these
compounds showed a plateau of activity of the 4 compounds at
24 hours (considered as 2 doses or more at.90%), suggesting that
all compounds were active #29 hours. Compounds 1, 2 and 6 at
MIC resulted in complete clearance of all parasites at #29 hours,
with compounds 1 and 2 displaying the fastest cidal activity, with a
maximum IC50 value reached at this point (Table 3). Compound 7
had similar IC50 values over each time interval investigated
however at the MIC not all parasites were cleared until 72 hours.
Although the MIC would shift slightly over time, at 24 and
48 hours there were 0.41% and 0.06% of the population
remaining, respectively. Additional profiling revealed these com-
pounds were cidal in nature and the speed of action was either
similar to, or faster than, the known drug, pentamidine. These
compounds will be profiled at reduced exposure times to
determine if the time to kill may be less than the exposure times
studied here. Estimation of the MIC at each time point would
clarify complete parasite clearance.
Collation of all of the analyses completed led to the selection of
five priority classes: phenylthiazol-4-ylethylamide, phenoxymethyl-
benzamide, 6-aryl-3-aminopyrazine-2-carboxamide, pyrido-isoxa-
zol-2-ylanilide and aminoethyl benzoylarylguanidine. In summary,
these compounds are novel scaffolds for HAT early drug
development and represent attractive templates for further
biological analysis and medicinal chemistry optimization, to build
structure-activity relationships for compounds active against T.b.
brucei. Upon confirmation of SAR, the chemistry program would
be extended to optimize potency and solubility, in conjunction
with early in vitro absorption, distribution, metabolism, elimination
(ADME) and toxicity assays. Early pharmacokinetic studies (PK),
to measure of brain compound levels, as well as in vivo efficacy
studies in HAT murine models, would follow upon identification
of suitable candidates. Medicinal chemistry efforts are being
actively pursued to synthesize new compounds from the starting
points discussed here, in a bid to generate leads with improved
physicochemical and biological properties. Chemical structures
and biological activities of all compounds defined as actives in the
T.b. brucei primary screening campaign at $80% activity (1217),
which were retested in dose-response in both the T. b. brucei assay
and the HEK293 cytotoxicity assay are available in the
CHEMBL-NTD database https://www.ebi.ac.uk/chemblntd.
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